Feasibility, Safety, and Tolerability of Two Modalities of Plasma Exchange with Albumin Replacement to Treat Elderly Patients with Alzheimer's Disease in the AMBAR Study
Journal of clinical apheresis(2022)
Abstract
In the Alzheimer Management by Albumin Replacement (AMBAR) study, mild‐to‐moderate Alzheimer's disease (AD) patients were treated with a plasma exchange (PE) program. Feasibility and safety of PE in this specific population are poorly understood and were analyzed in detail in this study.
MoreTranslated text
Key words
adverse event,Alzheimer's disease,apheresis,cognition,dementia,intravenous immunoglobulin,plasma exchange,plasmapheresis,venous access
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined